NEW SUBSTANCES OF ABUSE IN EUROPE

Results from a EUROPAD Pilot Study in Four Countries

Jody L. Green, PhD

Director of Research Administration

Denver Health & Hospital Authority, Denver CO USA

10 November 2013

Background – RADARS® System


- Researched Abuse,
 Diverted and Addiction-Related Surveillance
- Independently owned & operated



 Conducting prescription drug abuse, misuse and diversion surveillance in the United States since 2001


Background – RADARS® System

- Guided by external Scientific Advisory Board
- Qualified Principal Investigator for each program




 Provide common ground for Industry, Regulatory Agencies, Academics and Clinicians

United States RADARS® System Mosaic Approach




United States RADARS® System Mosaic Approach




REVIEW OF OPIOID AND STIMULANT TRENDS IN THE UNITED STATES

Have we reached the plateau?

URDD per quarter by drug for each state




URDD per quarter by drug for each state




Overall Opioid Abuse Trends in United States Population Rates, 2002-2012

Population Rate


Availability Rate (URDD)




The RADARS® System Treatment Programs-Population Rate – All Opioids 2009 Q1 through 2013 Q2



Treatment Programs- Population Rate by Drug 2009 Q1 through 2013 Q2




The RADARS® System Treatment Programs— URDD Rate – All Opioids 2009 Q1 through 2013 Q2




The RADARS® System Opioids

Treatment Programs— URDD Rate by Drug 2009 Q1 through 2013 Q2




UPDATE TO ABUSE DETERRENT FORMULATION DATA


Treatment Programs, Population Rate OxyContin®, Opana® ER, Other Opioids




Treatment Programs, URDD Rate OxyContin®, Opana® ER, Other Opioids




Drug Diversion, Population Rate OxyContin®, Opana® ER, Other Opioids



Drug Diversion, URDD Rate OxyContin®, Opana® ER, Other Opioids




Poison Center Intentional Exposures, Population Rate OxyContin®, Opana® ER, Other Opioids




Poison Center Intentional Exposures, URDD Rate

OxyContin®, Opana® ER, Other Opioids




Poison Center Intentional <u>Abuse</u>, Population Rate OxyContin®, Opana® ER, Other Opioids




Poison Center Intentional <u>Abuse</u>, URDD Rate


OxyContin®, Opana® ER, Other Opioids



United States RADARS® System Mosaic Approach



United States RADARS® System Mosaic Approach











Collaboration with EUROPAD begins (2010)




EUROPAD PILOT STUDY

European Opiate Addiction Treatment Association







STUDY INVESTIGATORS





Icro
Maremmani
Study investigator leader



Marilena
Guareschi
Study Investigator Leader



Pierre Villèger FRANCE



Didier
Touzeau
FRANCE (METRO PARIS)



Stephan Walcher



Lorenzo
Somaini
ITALY (PIEMONTE REGION)



Gaetano
Deruvo
Italy (Puglia Region)



Francesca Fonseca SPAIN

EUROPAD Survey

Study Objective

 assess overall rates and trends of prescription drug misuse in European countries

Study Methods

- Survey newly-enrolled patients (at intake) about their recent use of prescription drugs to get "high"
- Data collected from January 2012 through August 2013


EUROPAD Survey

Includes:

- Demographic information
- Treatment history
- Primary drug used to get high before coming to program
- Past 30-day use to get high and if injected

1 What is today's date?	Day	Mon	thYear 20							
2 What is your gender?	☐ Ma	ie 🗆	Female							
3 What is your age?										
4 What is the POSTAL CODE of your current address?										
5 Before coming to this	process	when we	ere you lest in an drug to	estment or	ogram? (c	theck ONE)				
MORE than 1 month		_	58 than or exactly 1 mor		☐ Neve					
6 Are you a health care	professio	mal?	Yes No							
7 Check the ONE drug (your PR	MARY D	RUG) that you used the	most to ge	t high wit	h before coming to this pro	gram.			
Buprenorphine	_	eroin		thadone	_		drylpheni	date		
☐ Codeine		ydrocodo	re Mo	phire		Tramedol				
Fentanyl						Other				
Fentanyl Hydromorphone Ctrycodone Cther										
Please anni	er these	question	a about your drug use in	the last 3	0 days by	checking the correct box	es).			
BUPMENDAPHINE	per	(gate)	HERON	Used in	Market	OEYCODON	Fresh park park	igada		
thed to get high	12	200	Used to get top		200	Used to get by		200		
Parmulation Unitrown	_		Heroin (any form)	-	-	Pormulation Universe	-			
Supremption, type unknown				_	_	Copustore, type unto own				
Tables	=			Deed in		Tables/Capsules CoyCord-6	0			
Sacronet			HYDROCODONE	peri	1000	Options	-	H		
Suissier®			Used to get high	1	100	Openia opposite block	_			
Temperati			Hydrocodone (any form)		-	capeutes	0	0		
Policies	_					Other organisms introduceparter not belied here				
Turnied/Amparé Oter Inpreseptive bilate not				Seed in						
lated here			HYDROMORPHONE and and to per logic l		in part	COMORPHONE	peril	270		
	Used in				-	Used to get high	to part	Month		
CODEINE Usedio pri hyb		in part Marin			_	Chymosphore (pay flore)		_		
Permutation Unitropen	Nage.		Hydromorphone, type unknown Todana							
Colore, type unknown			Arrest				Unatin	-		
Tables			Other hydromorphore brisis			TRAMADOL Usedio getispo		1		
Lonario®						Permulation Universe				
Lonand 198		0				Tramedit, type		0		
Other coderie ballets nutritied from	_	_		Used in		TeleralCredaperación Tale				
Facial Repositories			METHADONE Used to pathops	pasi	in part	Contamate/Contamal 898				
Linetiff		_		12		Teares				
Other codette recital suppositiones not light here	0		Methodore (any form)			Secret				
suppositiones not listed here					_	Other barrador bothers and based				
PENTANYL	Decide:	Herbert	MORPHE	es per	Name of	Solution Intended for				
Umedio get high		P part	Usedio get is		Total Seed	Ordense C	0	_		
Permutation Uniterioris			Formulation Unknown				-			
Penkryl, Igne unknown	_	0	Morphine, Type unknown							
Tables			Tables MECondrel/Moscordrel		-					
Alminett		0	ES CARRON SINCARA		-		Seetle			
Effective B		0	Ownorph@/Ownorph.876			METHYLPHENDATE Conditional Rep.	- march	in part		
Lottoma Adult			Severate	-			146			
Cities because tellipsop and balled	-	H	Beard / Bear 199	-	-	Pornutation Unitroven Methylpheristrin, type	-	_		
February			Other morphise ballets and bile		-	Tableto				
Dangenit			less.			Guerra / Spanne		0		
Performance		0				Concessed:	ö	0		
Mairfer®	_	0		Statute / Statute	-	0				
Other ferriangl patch not fished feets	0	0				Other methylpheretate latiness and lated here		-		

FRANCE



GERMANY



Total Surveys =

ITALY


n=318

744


SPAIN



EUROPAD Number of Surveys By Country By Year Quarter




Demographic Information




	France	Germany	Italy	Spain	Total
Mean Age (SD)	38.9(8.0)	36.8(9.8)	27.8(7.6)	38.9(9.1)	33.8(9.9)
Gender (%male)	77.8%	63.3%	67.3%	77.2%	70.2%


Primary Endpoints


- Primary Drug = "used the most to get high with before coming to this program"
 - Each patient can report ONLY ONE primary drug
- Endorsed Drug = "used in past month (or 90 days) to get high"
 - Each patient can report MULTIPLE endorsements






Number of Endorsements by Drug All Surveys (n=744)





EUROPAD Drug Rankings by Country

Rank	France	Germany	Italy	Spain	Total
1	Heroin	Heroin	Heroin	Heroin	Heroin
2	Buprenorphine	Methadone	Buprenorphine	Methadone	Methadone
3	Codeine	Fentanyl	Methadone	Codeine	Buprenorphine
4	Methadone	Buprenorphine	Codeine	Tramadol	Fentanyl
5	Morphine	Tramadol	Tramadol	Buprenorphine	Codeine
6	Fentanyl	Morphine	Fentanyl	Morphine	Tramadol
7	Tramadol	Codeine	Hydrocodone	Fentanyl	Morphine
8	Methylphenidate	Oxycodone	Oxycodone	Hydrocodone	Oxycodone
9	Oxycodone	Methylphenidate	Hydromorphone	Hydromorphone	Hydrocodone
10	Hydrocodone	Hydrocodone	Methylphenidate	Methylphenidate	Methylphenidate
11	Hydromorphone	Hydromorphone	Oxymorphone	Oxycodone	Hydromorphone
12	Oxymorphone	Oxymorphone	Morphine	Oxymorphone	Oxymorphone



Key Findings

- Mean age is 33.8 years, however Italy appears to have a younger patient population (27.8 years)
- Gender is similar across 4 countries studied (male 63-79% of respondents)
- Heroin is by far highest reported endorsed drug, primary drug and injection
- Drug endorsements vary depending on country fentanyl concentrated in Germany
- Drug rankings much different than United States
- Pilot Study proof of concept successful!

Limitations

- Small samples from each country
- Multiple languages lost in translation?
- Distinction between general use of drug versus use "to get high"
- Variation in drug availability in each country
- Variation in cultural considerations in each country



Expanding EUROPAD Study



Future of EUROPAD Study

Expanding from pilot into full program

- Feedback from study investigators
- Survey revisions
 - Clarify instructions and definitions
 - Add questions regarding treatment history and medications
- Additional sites in currently participating countries (increased number of surveys)
- Expansion into other countries (Norway, United Kingdom)

Grazie! Danke! Mercil Gracias! Thank You!

Inquiries: Jody.Green@RMPDC.org